{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:31:23Z","timestamp":1781620283521,"version":"3.54.5"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T00:00:00Z","timestamp":1599955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T00:00:00Z","timestamp":1599955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12149-020-01521-3","type":"journal-article","created":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T21:02:43Z","timestamp":1600030963000},"page":"707-717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The contribution of metabolic parameters of FDG PET\/CT prior and during therapy of adult patients with lymphomas"],"prefix":"10.1007","volume":"34","author":[{"given":"Juan Carlos","family":"Prieto Prieto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Vallejo Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftheria","family":"Hatzimichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Fotopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios-Nikiforos","family":"Kiortsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2184-4945","authenticated-orcid":false,"given":"Chrissa","family":"Sioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,13]]},"reference":[{"issue":"10091","key":"1521_CR1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298\u2013310.","journal-title":"Lancet"},{"issue":"27","key":"1521_CR2","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1521_CR3","first-page":"1023","volume":"61","author":"SA Rosenberg","year":"1977","unstructured":"Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep. 1977;61(6):1023\u20137.","journal-title":"Cancer Treat Rep"},{"issue":"1","key":"1521_CR4","first-page":"43","volume":"17","author":"JA Moormeier","year":"1990","unstructured":"Moormeier JA, Williams SF, Golomb HM. The staging of non-Hodgkin's lymphomas. Semin Oncol. 1990;17(1):43\u201350.","journal-title":"Semin Oncol"},{"issue":"14","key":"1521_CR5","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","volume":"28","author":"M Ziepert","year":"2010","unstructured":"Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373\u201380.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1521_CR6","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJMoa032520","volume":"350","author":"IS Lossos","year":"2004","unstructured":"Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350(18):1828\u201337.","journal-title":"N Engl J Med"},{"issue":"17","key":"1521_CR7","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2009.26.1693","volume":"28","author":"T Relander","year":"2010","unstructured":"Relander T, Johnson NA, Farinha P, et al. Prognostic factors in follicular lymphoma. J Clin Oncol. 2010;28(17):2902\u201313.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1521_CR8","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258\u201365.","journal-title":"Blood"},{"issue":"27","key":"1521_CR9","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555\u2013622.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1521_CR10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","volume":"132","author":"E Bachy","year":"2018","unstructured":"Bachy E, Maurer MJ, Habermann TM, et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018;132(1):49\u201358.","journal-title":"Blood"},{"issue":"6","key":"1521_CR11","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1053\/j.seminoncol.2018.01.005","volume":"44","author":"HJA Adams","year":"2017","unstructured":"Adams HJA, Kwee TC. An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma. Semin Oncol. 2017;44(6):404\u201319.","journal-title":"Semin Oncol"},{"issue":"6","key":"1521_CR12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/eci.12439","volume":"45","author":"C Sioka","year":"2015","unstructured":"Sioka C, Assimakopoulos A, Fotopoulos A. The diagnostic role of (18)F fluorodeoxyglucose positron emission tomography in patients with fever of unknown origin. Eur J Clin Invest. 2015;45(6):601\u20138.","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"1521_CR13","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/RLU.0000000000002654","volume":"44","author":"AH Katsanos","year":"2019","unstructured":"Katsanos AH, Alexiou GA, Fotopoulos AD, Jabbour P, Kyritsis AP, Sioka C. Performance of 18F-FDG, 11C-methionine, and 18F-FET PET for Glioma grading: a meta-analysis. Clin Nucl Med. 2019;44(11):864\u20139.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"1521_CR14","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3390\/cancers6041821","volume":"6","author":"A Gallamini","year":"2014","unstructured":"Gallamini A, Zwarthoed C, Borra A. Positron emission tomography (PET) in oncology. Cancers (Basel). 2014;6(4):1821\u201389.","journal-title":"Cancers (Basel)"},{"issue":"14","key":"1521_CR15","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1200\/JCO.2010.32.5225","volume":"29","author":"BD Cheson","year":"2012","unstructured":"Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2012;29(14):1844\u201354.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1521_CR16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00431-013-1993-8","volume":"172","author":"C Sioka","year":"2013","unstructured":"Sioka C. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood. Eur J Pediatr. 2013;172(6):733\u20138.","journal-title":"Eur J Pediatr"},{"issue":"5","key":"1521_CR17","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s13139-018-0543-8","volume":"52","author":"HJ Kim","year":"2018","unstructured":"Kim HJ, Lee R, Choi H, et al. Application of quantitative indexes of FDG PET to treatment response evaluation in indolent lymphoma. Nucl Med Mol Imaging. 2018;52(5):342\u20139.","journal-title":"Nucl Med Mol Imaging"},{"issue":"7","key":"1521_CR18","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00259-018-3953-z","volume":"45","author":"H Ilyas","year":"2018","unstructured":"Ilyas H, Mikhaeel NG, Dunn JT, et al. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45(7):1142\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"59","key":"1521_CR19","doi-asserted-by":"crossref","first-page":"99587","DOI":"10.18632\/oncotarget.20447","volume":"8","author":"CC Chang","year":"2017","unstructured":"Chang CC, Cho SF, Chuang YW, et al. Prognostic significance of total metabolic tumor volume on (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. Oncotarget. 2017;8(59):99587\u2013600.","journal-title":"Oncotarget"},{"issue":"50","key":"1521_CR20","doi-asserted-by":"crossref","first-page":"83544","DOI":"10.18632\/oncotarget.13180","volume":"7","author":"M Zhou","year":"2016","unstructured":"Zhou M, Chen Y, Huang H, Zhou X, Liu J, Huang G. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in diffuse large B-cell lymphoma. Oncotarget. 2016;7(50):83544\u201353.","journal-title":"Oncotarget"},{"issue":"1","key":"1521_CR21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnmt.119.231118","volume":"48","author":"MR Camacho","year":"2020","unstructured":"Camacho MR, Etchebehere E, Tardelli N, et al. Validation of a multifocal segmentation method for measuring metabolic tumor volume in Hodgkin lymphoma. J Nucl Med Technol. 2020;48(1):30\u20135.","journal-title":"J Nucl Med Technol"},{"issue":"9","key":"1521_CR22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1179\/1607845415Y.0000000033","volume":"21","author":"M Xie","year":"2016","unstructured":"Xie M, Zhai W, Cheng S, Zhang H, Xie Y, He W. Predictive value of F-18 FDG PET\/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma. Hematology. 2016;21(9):99\u2013105.","journal-title":"Hematology"},{"issue":"8","key":"1521_CR23","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1080\/10428194.2018.1562181","volume":"60","author":"P Islam","year":"2019","unstructured":"Islam P, Goldstein J, Flowers CR. PET-derived tumor metrics predict DLBCL response and progression-free survival. Leuk Lymphoma. 2019;60(8):1965\u201371.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1521_CR24","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12032-014-0446-1","volume":"32","author":"M Xie","year":"2015","unstructured":"Xie M, Wu K, Liu Y, Jiang Q, Xie Y. Predictive value of F-18 FDG PET\/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants. Med Oncol. 2015;32(1):446.","journal-title":"Med Oncol"},{"issue":"1","key":"1521_CR25","first-page":"22","volume":"31","author":"AM Garcia Vicente","year":"2012","unstructured":"Garcia Vicente AM, Bellon Guardia M, Soriano Castrejon A, et al. 18F-FDG-PET\/CT in the surveillance of patients with lymphoma: detection of asymptomatic recurrences. Rev Esp Med Nucl Imagen Mol. 2012;31(1):22\u20137.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"3","key":"1521_CR26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.crad.2015.11.019","volume":"71","author":"SH Kwon","year":"2016","unstructured":"Kwon SH, Kang DR, Kim J, et al. Prognostic value of negative interim 2-[(1)(8)F]-fluoro-2-deoxy-d-glucose PET\/CT in diffuse large B-cell lymphoma. Clin Radiol. 2016;71(3):280\u20136.","journal-title":"Clin Radiol"},{"issue":"10","key":"1521_CR27","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1\u201334.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1521_CR28","doi-asserted-by":"crossref","first-page":"e0210224","DOI":"10.1371\/journal.pone.0210224","volume":"14","author":"B Guo","year":"2019","unstructured":"Guo B, Tan X, Ke Q, Cen H. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis. PLoS ONE. 2019;14(1):e0210224.","journal-title":"PLoS ONE"},{"issue":"1","key":"1521_CR29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2017-04-773838","volume":"131","author":"M Akhtari","year":"2018","unstructured":"Akhtari M, Milgrom SA, Pinnix CC, et al. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood. 2018;131(1):84\u201394.","journal-title":"Blood"},{"issue":"3","key":"1521_CR30","first-page":"272","volume":"3","author":"SA Esfahani","year":"2013","unstructured":"Esfahani SA, Heidari P, Halpern EF, Hochberg EP, Palmer EL, Mahmood U. Baseline total lesion glycolysis measured with (18)F-FDG PET\/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. Am J Nucl Med Mol Imaging. 2013;3(3):272\u201381.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"1521_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2016.01.010","volume":"42","author":"MK Song","year":"2016","unstructured":"Song MK, Yang DH, Lee GW, et al. High total metabolic tumor volume in PET\/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era. Leuk Res. 2016;42:1\u20136.","journal-title":"Leuk Res"},{"issue":"7","key":"1521_CR32","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1521_CR33","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.27855","volume":"119","author":"TM Kim","year":"2013","unstructured":"Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer. 2013;119(6):1195\u2013202.","journal-title":"Cancer"},{"issue":"3","key":"1521_CR34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13139-014-0280-6","volume":"48","author":"J Kim","year":"2014","unstructured":"Kim J, Hong J, Kim SG, et al. Prognostic value of metabolic tumor volume estimated by (18) F-FDG positron emission tomography\/computed tomography in patients with diffuse large B-cell lymphoma of stage II or III disease. Nucl Med Mol Imaging. 2014;48(3):187\u201395.","journal-title":"Nucl Med Mol Imaging"},{"issue":"6","key":"1521_CR35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s12149-018-1260-1","volume":"32","author":"A Parvez","year":"2018","unstructured":"Parvez A, Tau N, Hussey D, Maganti M, Metser U. (18)F-FDG PET\/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin's lymphoma as predictors of treatment outcome and survival. Ann Nucl Med. 2018;32(6):410\u20136.","journal-title":"Ann Nucl Med"},{"issue":"5","key":"1521_CR36","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00277-011-1357-2","volume":"91","author":"MK Song","year":"2012","unstructured":"Song MK, Chung JS, Shin HJ, et al. Clinical significance of metabolic tumor volume by PET\/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91(5):697\u2013703.","journal-title":"Ann Hematol"},{"issue":"7","key":"1521_CR37","first-page":"528","volume":"40","author":"CY Ding","year":"2018","unstructured":"Ding CY, Guo Z, Sun J, Yang WP, Li TR. Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma. Zhonghua Zhong Liu Za Zhi. 2018;40(7):528\u201333.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"6","key":"1521_CR38","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/ejh.12467","volume":"94","author":"HJ Adams","year":"2015","unstructured":"Adams HJ, de Klerk JM, Fijnheer R, et al. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET\/CT metrics in diffuse large B-cell lymphoma. Eur J Haematol. 2015;94(6):532\u20139.","journal-title":"Eur J Haematol"},{"issue":"5","key":"1521_CR39","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/ejh.12268","volume":"92","author":"R Gallicchio","year":"2014","unstructured":"Gallicchio R, Mansueto G, Simeon V, et al. F-18 FDG PET\/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. Eur J Haematol. 2014;92(5):382\u20139.","journal-title":"Eur J Haematol"},{"issue":"3","key":"1521_CR40","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s13139-017-0503-8","volume":"52","author":"YS Park","year":"2018","unstructured":"Park YS, Lee SM, Park JS, Bae SK, Shim HK, Lee WS. Evaluating the predictive ability of initial staging F-18 FDG PET\/CT for the prognosis of non-Hodgkin Malignant lymphoma patients who underwent stem cell transplantation. Nucl Med Mol Imaging. 2018;52(3):216\u201323.","journal-title":"Nucl Med Mol Imaging"},{"issue":"8","key":"1521_CR41","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3109\/0284186X.2014.927074","volume":"53","author":"X Wu","year":"2014","unstructured":"Wu X, Pertovaara H, Korkola P, et al. Early interim PET\/CT predicts post-treatment response in diffuse large B-cell lymphoma. Acta Oncol. 2014;53(8):1093\u20139.","journal-title":"Acta Oncol"},{"issue":"4","key":"1521_CR42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00277-012-1640-x","volume":"92","author":"DH Yang","year":"2013","unstructured":"Yang DH, Ahn JS, Byun BH, et al. Interim PET\/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Ann Hematol. 2013;92(4):471\u20139.","journal-title":"Ann Hematol"},{"issue":"5","key":"1521_CR43","first-page":"1342","volume":"26","author":"YY Zhang","year":"2018","unstructured":"Zhang YY, Chen WY, Cui YP, et al. Value of (18)F-FDG PET\/CT scan quantization parameters for prognostic evaluation of patients with diffuse large B-cells lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018;26(5):1342\u20132249.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"9","key":"1521_CR44","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/ajh.23267","volume":"87","author":"S Park","year":"2012","unstructured":"Park S, Moon SH, Park LC, et al. The impact of baseline and interim PET\/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma. Am J Hematol. 2012;87(9):937\u201340.","journal-title":"Am J Hematol"},{"issue":"2","key":"1521_CR45","first-page":"1411","volume":"16","author":"LF Onate-Ocana","year":"2018","unstructured":"Onate-Ocana LF, Cortes V, Castillo-Llanos R, et al. Metabolic tumor volume changes assessed by interval (18)fluorodeoxyglucose positron emission tomography-computed tomography for the prediction of complete response and survival in patients with diffuse large B-cell lymphoma. Oncol Lett. 2018;16(2):1411\u20138.","journal-title":"Oncol Lett"},{"issue":"1","key":"1521_CR46","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1148\/radiol.2015150689","volume":"280","author":"R Minamimoto","year":"2016","unstructured":"Minamimoto R, Fayad L, Advani R, et al. Diffuse large B-cell lymphoma: prospective multicenter comparison of early interim FLT PET\/CT versus FDG PET\/CT with IHP, EORTC, deauville, and PERCIST criteria for early therapeutic monitoring. Radiology. 2016;280(1):220\u20139.","journal-title":"Radiology"},{"issue":"30","key":"1521_CR47","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34(30):3618\u201326.","journal-title":"J Clin Oncol"},{"key":"1521_CR48","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.2147\/CMAR.S216445","volume":"11","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhao Z, Li J, et al. Prognostic values of baseline, interim and end-of therapy (18)F-FDG PET\/CT in patients with follicular lymphoma. Cancer Manag Res. 2019;11:6871\u201385.","journal-title":"Cancer Manag Res"},{"issue":"5","key":"1521_CR49","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12149-018-1243-2","volume":"32","author":"S Annunziata","year":"2018","unstructured":"Annunziata S, Cuccaro A, Tisi MC, Hohaus S, Rufini V. FDG-PET\/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). Ann Nucl Med. 2018;32(5):372\u20137.","journal-title":"Ann Nucl Med"},{"issue":"10","key":"1521_CR50","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s10147-019-01482-2","volume":"24","author":"M Tatsumi","year":"2019","unstructured":"Tatsumi M, Isohashi K, Matsunaga K, et al. Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma. Int J Clin Oncol. 2019;24(10):1292\u2013300.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"1521_CR51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00277-015-2553-2","volume":"95","author":"HJA Adams","year":"2016","unstructured":"Adams HJA, Nievelstein RAJ, Kwee TC. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review. Ann Hematol. 2016;95(1):11\u20138.","journal-title":"Ann Hematol"},{"key":"1521_CR52","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-015-1193-1","volume":"15","author":"SH Jung","year":"2015","unstructured":"Jung SH, Ahn JS, Kim YK, et al. Prognostic significance of interim PET\/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. BMC Cancer. 2015;15:198.","journal-title":"BMC Cancer"},{"issue":"45","key":"1521_CR53","doi-asserted-by":"crossref","first-page":"79337","DOI":"10.18632\/oncotarget.18107","volume":"8","author":"MK Song","year":"2017","unstructured":"Song MK, Chung JS, Yhim HY, et al. Tumor necrosis and complete resection has significant impacts on survival in patients with limited-stage upper aerodigestive tract NK\/T cell lymphoma. Oncotarget. 2017;8(45):79337\u201346.","journal-title":"Oncotarget"},{"issue":"3","key":"1521_CR54","doi-asserted-by":"crossref","first-page":"e0194435","DOI":"10.1371\/journal.pone.0194435","volume":"13","author":"H Wang","year":"2018","unstructured":"Wang H, Shen G, Jiang C, Li L, Cui F, Tian R. Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET\/CT parameters in extranodal natural killer\/T-cell lymphoma: a meta-analysis. PLoS ONE. 2018;13(3):e0194435.","journal-title":"PLoS ONE"},{"issue":"11","key":"1521_CR55","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/bloodadvances.2018017681","volume":"2","author":"CC Pinnix","year":"2018","unstructured":"Pinnix CC, Ng AK, Dabaja BS, et al. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018;2(11):1334\u2013433.","journal-title":"Blood Adv"},{"issue":"4","key":"1521_CR56","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.14728","volume":"178","author":"L Ceriani","year":"2017","unstructured":"Ceriani L, Martelli M, Conconi A, et al. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET\/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. Br J Haematol. 2017;178(4):588\u201391.","journal-title":"Br J Haematol"},{"issue":"8","key":"1521_CR57","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood-2014-12-616474","volume":"126","author":"L Ceriani","year":"2015","unstructured":"Ceriani L, Martelli M, Zinzani PL, et al. Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126(8):950\u20136.","journal-title":"Blood"},{"issue":"7","key":"1521_CR58","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12149-019-01354-9","volume":"33","author":"D Albano","year":"2019","unstructured":"Albano D, Bosio G, Bianchetti N, et al. Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in mantle cell lymphoma. Ann Nucl Med. 2019;33(7):449\u201358.","journal-title":"Ann Nucl Med"},{"issue":"1","key":"1521_CR59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hon.2563","volume":"37","author":"D Albano","year":"2019","unstructured":"Albano D, Bosio G, Camoni L, et al. Prognostic role of baseline (18) F-FDG PET\/CT parameters in MALT lymphoma. Hematol Oncol. 2019;37(1):39\u201346.","journal-title":"Hematol Oncol"},{"issue":"1","key":"1521_CR60","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00259-018-4173-2","volume":"46","author":"D Albano","year":"2019","unstructured":"Albano D, Bosio G, Pagani C, et al. Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in Burkitt lymphoma. Eur J Nucl Med Mol Imaging. 2019;46(1):87\u201396.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1521_CR61","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s12149-019-01338-9","volume":"33","author":"D Albano","year":"2019","unstructured":"Albano D, Re A, Tucci A, Giubbini R, Bertagna F. Prognostic role of DeltaMTV and DeltaTLG in Burkitt lymphoma. Ann Nucl Med. 2019;33(4):280\u20137.","journal-title":"Ann Nucl Med"},{"key":"1521_CR62","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1186\/s12885-016-2672-8","volume":"16","author":"S Watanabe","year":"2016","unstructured":"Watanabe S, Manabe O, Hirata K, et al. The usefulness of (18)F-FDG PET\/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD). BMC Cancer. 2016;16:635.","journal-title":"BMC Cancer"},{"issue":"4","key":"1521_CR63","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1515\/raon-2016-0045","volume":"50","author":"K Okuyucu","year":"2016","unstructured":"Okuyucu K, Ozaydin S, Alagoz E, et al. Prognosis estimation under the light of metabolic tumor parameters on initial FDG-PET\/CT in patients with primary extranodal lymphoma. Radiol Oncol. 2016;50(4):360\u20139.","journal-title":"Radiol Oncol"},{"issue":"1","key":"1521_CR64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjoto.2017.10.009","volume":"39","author":"K Pak","year":"2018","unstructured":"Pak K, Kim BS, Kim K, et al. Prognostic significance of standardized uptake value on F18-FDG PET\/CT in patients with extranodal nasal type NK\/T cell lymphoma: a multicenter, retrospective analysis. Am J Otolaryngol. 2018;39(1):1\u20135.","journal-title":"Am J Otolaryngol"},{"issue":"11","key":"1521_CR65","first-page":"831","volume":"41","author":"LL Wu","year":"2019","unstructured":"Wu LL, Liang JH, Wang L, Xu W, Ding CY. Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK\/T cell lymphoma. Zhonghua Zhong Liu Za Zhi. 2019;41(11):831\u20136.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"3","key":"1521_CR66","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4274\/mirt.48658","volume":"26","author":"E Alagoz","year":"2017","unstructured":"Alagoz E, Okuyucu K, Ince S, et al. Uptake patterns of untreated primary gastrointestinal extranodal lymphomas on initial staging (18)F-FDG PET\/CT and metabolic tumor parameters. Mol Imaging Radionucl Ther. 2017;26(3):83\u201392.","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"9","key":"1521_CR67","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00259-013-2443-6","volume":"40","author":"CY Kim","year":"2013","unstructured":"Kim CY, Hong CM, Kim DH, et al. Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on (1)(8)F-FDG PET\/CT in patients with extranodal NK\/T-cell lymphoma. Eur J Nucl Med Mol Imaging. 2013;40(9):1321\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1521_CR68","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/10428194.2018.1488254","volume":"60","author":"A Castello","year":"2019","unstructured":"Castello A, Grizzi F, Qehajaj D, Rahal D, Lutman F, Lopci E. (18)F-FDG PET\/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors. Leuk Lymphoma. 2019;60(2):367\u201375.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"1521_CR69","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/cas.12282","volume":"104","author":"MK Song","year":"2013","unstructured":"Song MK, Chung JS, Lee JJ, et al. Metabolic tumor volume by positron emission tomography\/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma. Cancer Sci. 2013;104(12):1656\u201361.","journal-title":"Cancer Sci"},{"issue":"2","key":"1521_CR70","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijrobp.2016.10.029","volume":"97","author":"SA Milgrom","year":"2017","unstructured":"Milgrom SA, Dong W, Akhtari M, et al. Chemotherapy response assessment by FDG-PET-CT in early-stage classical Hodgkin lymphoma: moving beyond the five-point Deauville score. Int J Radiat Oncol Biol Phys. 2017;97(2):333\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"20","key":"1521_CR71","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","volume":"130","author":"AJ Moskowitz","year":"2017","unstructured":"Moskowitz AJ, Schoder H, Gavane S, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017;130(20):2196\u2013203.","journal-title":"Blood"},{"issue":"1","key":"1521_CR72","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bbmt.2017.09.006","volume":"24","author":"V Prochazka","year":"2018","unstructured":"Prochazka V, Gawande RS, Cayci Z, et al. Positron emission tomography-based assessment of metabolic tumor volume predicts survival after autologous hematopoietic cell transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2018;24(1):64\u201370.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1521_CR73","first-page":"207","volume":"2","author":"J Mettler","year":"2018","unstructured":"Mettler J, Muller H, Voltin CA, et al. Metabolic tumour volume for response prediction in advanced-stage Hodgkin lymphoma. J Nucl Med. 2018;2:207\u201311.","journal-title":"J Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-020-01521-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-020-01521-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-020-01521-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T23:23:10Z","timestamp":1631488990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-020-01521-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,13]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1521"],"URL":"https:\/\/doi.org\/10.1007\/s12149-020-01521-3","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,13]]},"assertion":[{"value":"25 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author(s) declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical aproval"}}]}}